Clinical Trials Logo

cT2a N0NxM0 Renal Tumor clinical trials

View clinical trials related to cT2a N0NxM0 Renal Tumor.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02597322 Completed - Clinical trials for cT2a N0NxM0 Renal Tumor

Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)

AXIPAN
Start date: February 2012
Phase: Phase 2
Study type: Interventional

Axitinib (AXITINIB) is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 which has achieved objective response rate of 44.2% in phase II study in cytokine-refractory metastatic renal-cell cancer patients. Pre-surgical treatment with Axitinib could allow a substantial proportion of patients with large organ confined tumors to benefit from NSS. The Objective is to determine the efficacy of Axitinib administered prior to surgery in patients with large organ confined tumors not primarily suitable for NSS (cT2aNoNxM0) for shifting from a radical nephrectomy indication to a nephron sparing procedure.